Germline testing is important in prostate cancer and evaluation can be complex.
We instituted a monthly multi-disciplinary virtual genetics tumor board (7/2021-3/2022). Participants and panelists were surveyed on usefulness and acceptability.
101 participants attended a session, and 77 follow-up surveys were completed. Over 90% participants and 100% panelists endorsed usefulness of the case discussions and usability of the technology. The majority felt it provided new information they will use.
A multidisciplinary genetics board was successfully developed to address complexity in prostate cancer genetics. The virtual platform may enhance dissemination of expertise where there are regional gaps.
Prostate cancer and prostatic diseases. 2024 Jan 03 [Epub ahead of print]
Stacy Loeb, Heather H Cheng, Channing J Paller, Emily Weg, Jennifer Johnson, Laura Gross, Scott W Keith, Jessica Russo, Feighanne Hathaway, Adrian Rivera, Veda N Giri
Department of Urology and Population Health, New York University and Manhattan Veterans Affairs, New York, NY, USA. ., Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA, USA., Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MA, USA., Department of Radiation Oncology, University of Washington, Seattle, WA, USA., Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA., Yale School of Medicine and Yale Cancer Center, New Haven, CT, USA., Division of Biostatistics and Bioinformatics, Sidney Kimmel Medical Colllege, Thomas Jefferson University, Philadelphia, PA, USA., MD Anderson Cancer Center at Cooper University Health Care, Camden, NJ, USA., Hematology/Oncology, Biological Sciences Division, University of Chicago, Chicago, IL, USA., Department of Urology and Population Health, New York University and Manhattan Veterans Affairs, New York, NY, USA.